Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
MEDICO

Medico Remedies Share Price

 

 

Medico Remedies live price: ₹47.6. It opened at ₹47 vs previous close ₹48; intraday high/low: ₹51/₹47. The 50 & 200 DMA stand at ₹43.41/₹45.66.

Medico Remedies Performance

  • Today's Low
  • ₹47
  • Today's High
  • ₹51
  • 52 Week Low
  • ₹30
  • 52 Week High
  • ₹59
  • Open Price₹47
  • Previous Close₹48
  • Volume450,355
  • 50 DMA₹43.41
  • 100 DMA₹44.00
  • 200 DMA₹45.66

Medico Remedies Chart

Investment Returns

  • Over 1 Month + 12.05%
  • Over 3 Month + 6.89%
  • Over 6 Month -8.65%
  • Over 1 Year -12.56%

Smart Investing Starts Here Start SIP with Medico Remedies for Steady Growth!

Invest Now

Medico Remedies Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 30.1
  • PEG Ratio
  • 1
  • Market Cap Cr
  • 395
  • P/B Ratio
  • 5.7
  • Average True Range
  • 2.53
  • EPS
  • 1.58
  • Dividend Yield
  • 0
  • MACD Signal
  • 1.6
  • RSI
  • 65.51
  • MFI
  • 82.11

Medico Remedies Financials

Medico Remedies Technicals

EMA & SMA

Current Price
₹47.60
-0.07 (-0.15%)
pointer
  • Bearish Moving Average 2
  • Bullish Moving Average 14
  • 20 Day
  • ₹45.12
  • 50 Day
  • ₹43.41
  • 100 Day
  • ₹44.00
  • 200 Day
  • ₹45.66

Resistance and Support

48.07 Pivot Speed
  • R3 51.03
  • R2 50.18
  • R1 48.92
  • S1 46.81
  • S2 45.96
  • S3 44.70

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Medico Remedies has an operating revenue of Rs. 206.38 Cr. on a trailing 12-month basis. An annual revenue growth of 38% is outstanding, Pre-tax margin of 9% is okay, ROE of 17% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 200DMA and around 16% above its 50DMA. It needs to stay above the 200DMA levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 4% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 86 which is a GOOD score indicating consistency in earnings, a RS Rating of 66 which is FAIR indicating the recent price performance, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 63 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Medico Remedies Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-21 Audited Results
2026-02-12 Quarterly Results
2025-11-14 Quarterly Results
2025-11-13 Quarterly Results
2025-08-08 Quarterly Results
Date Purpose Remarks
2023-03-16 Split Rs.0.00 split from Rs. 10/- to Rs. 2/-.
Date Purpose Remarks
2021-11-17 Bonus Rs.0.00 issue of equity shares in the ratio of 3:1 of Rs.. 10/-.

Medico Remedies Shareholding Pattern

61.38%
0.03%
23.56%
15.03%

Medico Remedies FAQs

Medico Remedies share price is ₹47 As on 01 June, 2026 | 16:42

The Market Cap of Medico Remedies is ₹395 Cr As on 01 June, 2026 | 16:42

The P/E ratio of Medico Remedies is 30.1 As on 01 June, 2026 | 16:42

The PB ratio of Medico Remedies is 5.7 As on 01 June, 2026 | 16:42

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23